Prognosis in Intracerebral Hemorrhage. The ICHCat Score in Primary Care.
NCT ID: NCT03247049
Last Updated: 2017-08-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
262 participants
OBSERVATIONAL
2015-07-27
2017-07-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Due to the characteristics of the population with ICH described in these works, it seems useful to propose a prognostic index (ICHCat) to identify the variables associated to its incidence and mortality and that, in addition, to make adjustments in the comparisons of the survival between different series of patients or different treatment modalities in primary care.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neurological Outcomes of Primary Intracerebral Haemorrhage
NCT03995940
Early Multimodal Neuromonitoring For Spontaneous Intracerebral Hemorrhage (ICH)
NCT05501613
Validation of the ICH Score for the Prediction of 12-month Functional Outcome in Patients With Primary Intracerebral Hemorrhage
NCT05808777
Longitudinal Cohort Study on ICH Care
NCT03183167
A Cohort Study of Patients With Intracranial Hemorrhage
NCT05760950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Predictor Variables
Predictor variables were considered if they were viewed as commonly measured and available in primary care and with potential evidence of an association with ICH risk. Candidate variables included:
Sex: woman (0) man (1) Age: \<80 year-old (1), ≥80 year-old (2). Number CCP criteria: \<4 (0) ≥4 (1). Charlson comorbidity index. Short version. Current medications were asked about during the home visit and confirmed in medical records. Polypharmacy (defined as five or more daily medications): \<5 (0), between 5-9 (1), and ≥10 (2). Oral anticoagulants (acenocumarol or warfarin) with TTR ≥60% (1), if TRT \<60% (2) or New Oral Anticoagulants NOACs (0). Antidepressants and/or, sedating or other drugs affecting the neurologic system: man (1), woman (2). If there was a diagnostic of "atrial fibrillation", CHA2DS2VASC and HAS-BLED scores were included.
Recurrent falls or fall risk: no (0), yes (1). Hypertension not controlled by therapy (≥ 160/90 mmHg): no (0), yes (1). BP was measured as an average of separated follow-up measurements last six months.
Alcoholism abuse vs dependence: no (0), yes (1) Presence de cognitive impairment: a disease-specific diagnosis of cognitive impairment and/or prescription of specific treatment, without specification of sub-type or severity, was used and mesured by Pfeiffer test \[2\]: \[0-2 errors\] = Intact Intellectual Functioning (1); \[≥3 errors\] = Mild to severe Intellectual Impairment (2)\].
Presence de disability: score in \[Barthel ≥60 (1) \<60 (2)\] or in \[Rankin \<4 (1) 5(2)\] were used to assess dependence in ADL Functional status: (0) Autonomus (1) Residual with caretaker (2) Dependence with caretaker (3) Long stay
Socio familiar risk: score in Gijon\[18\] scale 10-14 (1) ≥15 (2)\]
Primary Outcome Given the limited survival, the primary outcome was death all causes occurring within the 5-year follow-up after the ICH episode.
Predictions of ICH mortality risk were based on Cox proportional-hazards regression models. All potential predictors were considered in a multivariate logistic regression, and a backward step selection procedure was carried out to pick the variables that composed the best model. Subsequently design a predictive model of multivariate Cox regression analysis to define the weight of each of the pathologies in the mortality. To assign the weight according to the value HR took into account only those with a HR ≥1.2 in the multivariate model approximating the value of HR to the nearest whole number:
* HR between 1.20 and 1.49 scored with 1.
* HR between 1.50 and 2.49 with 2.
* HR between 2.50 and 3.49 received 3, and so on.
The final score for each patient (ICH) was made up of the sum of their scores by age and comorbidity. To check the validity of the index we define the following levels of mortality risk:
* Low risk: 0-1 points.
* Medium Risk: from 2 to 5 points.
* High Risk: of 6 or more points.
The authors estimate the survival probability of each risk group according to the Kaplan-Meier method and compared these curves using the Log-Rank test. It will be used ROC curves i the AUC to assess the ability of the index ICH to perform properly the assignment of patients to different risk groups. The hazard ratio according to the proportional hazards model categorized in their levels of risk, in order to observe the increase in the risk of death that occurs from a risk group to the next. The statistical analysis consisted of a multivariate logistic regression model. The model selection has been caried out with an AIC-led forward step selection method. To ensure internal validity, 20% of data has been discarded in the phase of constructing the model and only used to assess model performance using ROC curves and the AUC.
In a second phase, there will be a retrospective study of validation in the cohort of patients PCC of the territory with an episode of ICH.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
15 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Universidad Miguel Hernandez de Elche
OTHER
Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Josep Lluís Clua Espuny
PhD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
V Francisco Gil-Guillen, PhD
Role: STUDY_CHAIR
Universidad Miguel Hernandez
References
Explore related publications, articles, or registry entries linked to this study.
Gonzalez-Henares A, Clua-Espuny JL, Gil-Guillen VF, Panisello-Tafalla A, Queralt-Tomas ML, Ripolles-Vicente R, Lopez-Pablo C, Lucas-Noll J, Equipo de Investigacion Ebrictus Ede I. [Incidence and preventability of haemorrhagic strokes. Results of the Ebrictus register]. Rev Neurol. 2016 May 1;62(9):385-95. Spanish.
Lorman-Carbo B, Clua-Espuny JL, Muria-Subirats E, Ballesta-Ors J, Gonzalez-Henares MA, Fernandez-Saez J, Martin-Lujan FM; on behalf Ebrictus Research Group. Complex chronic patients as an emergent group with high risk of intracerebral haemorrhage: an observational cohort study. BMC Geriatr. 2021 Feb 5;21(1):106. doi: 10.1186/s12877-021-02004-4.
Gonzalez-Henares MA, Clua-Espuny JL, Lorman-Carbo B, Fernandez-Saez J, Queralt-Tomas L, Muria-Subirats E, Ballesta-Ors J, Gil-Guillen JV. Risk of Long-Term Mortality for Complex Chronic Patients with Intracerebral Hemorrhage: A Population-Based e-Cohort Observational Study. Adv Ther. 2020 Feb;37(2):833-846. doi: 10.1007/s12325-019-01206-y. Epub 2019 Dec 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IDIAP Jordi Gol code P16/087
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.